Efficacy of Electroacupuncture Versus Solifenacin Succinate for Female Overactive Bladder

• Status: Not yet recruiting
• Trial end date: 2025-03-31
• Target enrollment: 0
• Participant gender: Female

Summary

Through a scientific and standardized multicenter, blinding, double-dummy, randomized controlled, noninferiority clinical trial study method, the investigators evaluated electroacupuncture as a safe and effective non-pharmacological treatment for OAB in women by comparison with Solifenacin Succinate.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shanghai University of Traditional Chinese Medicine
• Collaborator: Longhua Hospital
• Treatments: Solifenacin Succinate

Criteria

Inclusion Criteria:

• Meet the American Urological Association (AUA) diagnostic criteria for adult overactive bladder disorder (non-neurogenic) and the Chinese Urological Association's Guidelines for the Diagnosis and Treatment of Urological Diseases in China (2014 edition) for OAB.

• Female patients aged 18-75 years.

• Duration of illness with OAB ≥ 3 months.

• 3≤OABSS≤11.

• No abnormality in routine urine tests.

• Patients had never received acupuncture treatment.

• No mental or intellectual abnormalities, able to understand the provisions of the scales and complete the assessment.

• Consent to participate in this study and sign a written informed consent.

Exclusion Criteria:

• Combination of more serious heart, liver, kidney and other serious diseases; Or patients with severe liver or kidney insufficiency.

• Patients with pelvic organ prolapse ≥ Ⅱ degree, urinary system surgery history or pelvic floor surgery history.

• Patients with other diseases presenting with OAB symptoms.

• Those with urinary diseases (such as calculi and tuberculosis of the bladder), malignant tumors, and neurological disorders.

• Patients who are pregnant or breastfeeding.

• Patients using medication that may affect bladder function one month prior to enrollment or having received behavioural therapy for OAB three months prior to enrolment, etc.

• Patients with pacemakers.

• Patients with blood diseases, diabetes mellitus or mental diseases.

• Infections, ulcers, abscesses, and skin infections at needling sites; metal allergy or extreme needle phobia.

• Participation in other clinical medical trial studies over the last month.